Meet Alfa Cytology at the Cancer R&D 2024, Nov 18-20, 2024. We look forward to connecting with you and providing expert solutions for your cancer drug development projects.
Learn More
Alfa Cytology offers efficient solutions for exploring leukemia biomarkers and provides valuable insights and approaches. Our services cover the entire process of leukemia biomarkers from discovery to validation, assisting you at any stage of the preclinical process. Reduce the time to discovery of novel biomarkers in the laboratory setting with our expertise and advanced platforms.
Biomarkers are indicators that reflect specific diseases. They encompass various types such as genes, proteins, hormones, and measurable substances. In leukemia, CD markers are the most prevalent biomarkers, including CD3, CD19, CD20, and CD33. CD markers are utilized for cell sorting, identification, and leukemia diagnosis. They play a crucial role in leukemia treatment, as therapeutic antibody drugs are designed to target cells with specific CD markers.
Fig. 1. Role of biomarkers in leukemia. (Small, S. et al., 2022)
We offer biomarker discovery, validation, and testing services for leukemia. Our advanced detection methods provide sensitive and selective identification and monitoring of specific leukemia biomarkers. The development of leukemia biomarkers involves three key steps: biomarker discovery, development of determination methods, and verification.
We offer the service of finding biomarkers for leukemia and support your plan to discover biomarkers of early leukemia. By analyzing body fluids or tissue samples from experimental animals, we can effectively monitor and measure leukemia-associated biomarkers present in the samples. We provide biotechnology and methods for the research and discovery of biomarkers.
| Methods | Service Details |
| Single cell sequencing | Utilizing our single-cell sequencing technique, we can identify novel leukemia biomarkers and detect alterations in gene expression that may serve as indicators of leukemia or predict disease progression and outcomes. |
| Mass spectrum | Our mass spectrometry technology utilizes high precision and specificity to identify effective leukemia biomarkers. By employing mass spectrometry, we can successfully discover biomarkers for leukemia. |
| Proteomics | Proteomics analysis of animal samples in leukemia enables the identification of specific and valuable biomarkers within the complete protein spectrum. |
| Metabolomics | Metabolic studies strive to identify metabolic markers specific to leukemia, with the goal of elucidating various biological processes associated with the disease. |
| Epigenetics | Epigenetics analysis examines DNA methylation, histone modification, and miRNA alterations in leukemia, aiming to identify potential biomarkers. |
| High-throughput omics | High-throughput genomics techniques enable the analysis of thousands of individual molecules, facilitating the identification of molecular markers associated with specific diseases. |
We possess a comprehensive verification method to validate candidate biomarkers. Leveraging our proteomics technology and advanced platform, we verify the efficacy of leukemia biomarkers, thereby facilitating their clinical translation.
Experiment design
Discovery phase
Verification phase
Validation phase
Explore the field of leukemia biomarker exploration and development with Alfa Cytology - your dependable and steadfast collaborative partner. Our comprehensive range of services facilitates in-depth analysis, unraveling the complex interplay between candidate biomarkers and the various leukemia indicators. Contact us to commence a journey that delves into your specific requirements, with customized solutions aligned with your unique objectives.
Reference